OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Average Rating of “Hold” from Analysts

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) have received a consensus rating of “Hold” from the five analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $5.6667.

A number of equities research analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of OKYO Pharma in a research note on Friday, July 17th. HC Wainwright decreased their price objective on shares of OKYO Pharma from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Monday, July 13th.

OKYO Pharma Price Performance

Shares of NASDAQ:OKYO opened at $1.55 on Monday. The business’s 50-day moving average is $1.58 and its 200 day moving average is $1.74. OKYO Pharma has a 1 year low of $1.34 and a 1 year high of $3.35.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new stake in shares of OKYO Pharma during the fourth quarter worth $36,000. Renaissance Technologies LLC increased its position in shares of OKYO Pharma by 235.0% in the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock valued at $286,000 after acquiring an additional 96,800 shares during the period. Finally, Citadel Advisors LLC acquired a new position in shares of OKYO Pharma in the 3rd quarter valued at $31,000. Hedge funds and other institutional investors own 2.97% of the company’s stock.

About OKYO Pharma

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.